SCHEMBL1344736

SCHEMBL1344736

O=C(O)Cc1nc(NC(=O)Nc2cnccc2C(=O)C2CCCC2)sc1Sc1ccccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 4/20 0.40
GCK P35557 3/20 0.38
CCNE1 P24864 5/20 0.36
CDK2 P24941 5/20 0.36
CDK5 Q00535 5/20 0.36
CNR1 P21554 1/20 0.35
ALDH1A1 P00352 2/20 0.35
ADORA3 P0DMS8 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM6B O15054 1/20 0.33
KDM4D Q6B0I6 1/20 0.33
KMT2A Q03164 2/20 0.32
MAPT P10636 2/20 0.32
GSK3B P49841 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
RORC P51449 1/20 0.32
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1340243 0.94 GCK (0.38) KDM4CGCKCCNE1CDK2CDK5
SCHEMBL1341894 0.92 GCK (0.40) GCKCCNE1CDK2CDK5ALDH1A1
SCHEMBL1341538 0.90 KDM4C (0.40) KDM4CGCKCCNE1CDK2CDK5
SCHEMBL1341296 0.88 KDM4C (0.41) KDM4CCCNE1CDK2CDK5CNR1
SCHEMBL1342041 0.88 KDM4C (0.36) KDM4CGCKCCNE1CDK2CDK5
SCHEMBL1341964 0.87 GCK (0.39) GCKALDH1A1ADORA3RAB9AL3MBTL1
SCHEMBL1344745 0.87 GCK (0.41) GCKCCNE1CDK2CDK5CNR1
SCHEMBL1342020 0.87 GCK (0.37) GCKALDH1A1ADORA3RAB9AL3MBTL1
SCHEMBL1340444 0.87 GCK (0.40) KDM4CGCKCNR1ALDH1A1ADORA3
SCHEMBL1342987 0.87 GCK (0.43) GCKALDH1A1ADORA3RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 KDM4C 1141/4885GCK 1/4885CCNE1 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.